Table 1 Studies and patients’ characteristics
From: Overweight and obesity in adult patients with phenylketonuria: a systematic review
First author, year | Design | Location | Funding sources | Matching criteria | Sample size | Treatment | Diagnosis context | Mean/median age (years) | ||
|---|---|---|---|---|---|---|---|---|---|---|
PKU | Controls | PKU | PKU | Controls | ||||||
Azabdaftari, 2019 [8] | Cross-sectional | Germany | Funds dedicated to clinical research | Age | 23 | 28 | Diet | NR | 30.8 ± 8.4 | 30.1 ± 9.1 |
Burton, 2018 [14] | Retrospective | USA | Pharmaceutical company | Age, race, gender, geographic location | 3691 | 18455 | NR | NR | 34.6 ± 14.3 | 34.9 ± 14.2 |
Trefz, 2019 [15] | Retrospective | Germany | Pharmaceutical company | Age and gender | 377 | 3770 | Diet + pharmacological treatment | NBS/clinical suspicion | 50.9 ± 20.4 | NR |
Robertson, 2013 [9] | Retrospective | UK | None | NA | 236 | NA | Diet | NBS | 26 ± 7 | NA |
Jani, 2017 [16] | Longitudinal | USA | NIH and Pharmaceutical company | NA | 27 | NA | Diet + pharmacological treatment | NR | 28.8 (19.5, 54.6) | NA |
Ozel, 2014 [17] | Retrospective and cross-sectional | Europe and Turkey | None | NA | 164 | NA | Diet + pharmacological treatment | NBS | 22.9(Ankara) 19.6(Brussels) | NA |
Couce, 2018 # [19] | Cross-sectional | Spain | APS fees covered by NPO | Age and gender | 41 | 25 | Diet + pharmacological treatment | NBS/clinical suspicion | NR | NR |
Williams, 2015 [18] | Cross-sectional | Australia | None | NA | 41 | NA | Diet | NR | 31 ± 12 | NA |